Multidrug-resistance proteins are weak tumor associated antigens for colorectal carcinoma

BMC Immunology

Volumn 12, Issue , 2011, Pages

  Mullins, Christina S ^a   Eisold, Sven ^a   Klar, Ernst ^a   Linnebacher, Michael ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Colorectal cancer; Immunotherapy; Multidrug resistance; Reverse immunology; T cell epitopes; Therapy resistance; Tumor antigens

Indexed keywords

CISPLATIN; EPITOPE; FLUOROURACIL; GAMMA INTERFERON; MATRIX PROTEIN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 3; MULTIDRUG RESISTANCE PROTEIN 5; PROTEIN P68; TUMOR ANTIGEN; GLYCOPROTEIN P; HLA A2 ANTIGEN; PEPTIDE;

ARTICLE; CD8+ T LYMPHOCYTE; CHEMOTHERAPY; COLORECTAL CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY TEST; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOLOGY; IN VITRO STUDY; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; TUMOR CELL; UPREGULATION; ANIMAL; BIOSYNTHESIS; CELL PROLIFERATION; CELL STRAIN 3T3; CELL STRAIN HCT116; CHEMISTRY; COLORECTAL TUMOR; CYTOTOXICITY; METABOLISM; MOUSE; TUMOR CELL LINE;

ANIMALS; ANTIGENS, NEOPLASM; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOTOXICITY, IMMUNOLOGIC; HCT116 CELLS; HLA-A2 ANTIGEN; HUMANS; INTERFERON-GAMMA; MICE; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NIH 3T3 CELLS; P-GLYCOPROTEINS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 79960048925     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-12-38     Document Type: Article

References (36)

1. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993, 62:385-427. 10.1146/annurev.bi.62.070193.002125, 8102521.
2. Krishna R, Mayer LD. Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci 2000, 11(4):265-83. 10.1016/S0928-0987(00)00114-7, 11033070.
3. Johnstone RW, Ruefli AA, Smyth MJ. Multiple physiological functions for multidrug transporter P-glycoprotein?. Trends Biochem Sci 2000, 25(1):1-6. 10.1016/S0968-0004(99)01493-0, 10637601.
4. Dean M. ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia 2009, 14(1):3-9. 10.1007/s10911-009-9109-9, 19224345.
5. Yamanaka R. Dendritic-cell- and peptide-based vaccination strategies for glioma. Neurosurg Rev 2009, 32(3):265-73. discussion 273, 10.1007/s10143-009-0189-1, 19214609.
6. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000, 60(4):829-33.
7. Greiner J, Schmitt A, Giannopoulos K, Rojewski MT, Götz M, Funk I, Ringhoffer M, Bunjes D, Hofmann S, Ritter G, Döhner H, Schmitt M. High-dose RHAMM-R3 peptide vaccination for patients with acute myeloid leukemia, myelodysplastic syndrome and multiple myeloma. Haematologica 2010, 95(7):1191-7. 10.3324/haematol.2009.014704, 2895045, 20081055.
8. Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW, Hofmann WK, Uharek L, Thiel E, Scheibenbogen C. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009, 113(26):6541-8. 10.1182/blood-2009-02-202598, 19389880.
9. Mano M, Humblet Y. Drug Insight: panitumumab, a human EGFR-targeted monoclonal antibody with promising clinical activity in colorectal cancer. Nat Clin Pract Oncol 2008, 5(7):415-25. 10.1038/ncponc1136, 18506165.
10. Gutierrez C, Schiff R. HER2: biology, detection, and clinical implications. Arch Pathol Lab Med 2011, 135(1):55-62.
11. Wu Y, Wang L, Zhang Y. Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy. Cell Mol Immunol 2004, 1(5):351-6.
12. O'Neill DW, Adams S, Bhardwaj N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004, 104(8):2235-46. 10.1182/blood-2003-12-4392, 15231572.
13. Vauleon E, Avril T, Collet B, Mosser J, Quillien V. Overview of cellular immunotherapy for patients with glioblastoma. Clin Dev Immunol 2010, 2010. pii: 689171.
14. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006, 24(31):5060-9. 10.1200/JCO.2006.07.1100, 17075125.
15. Klein O, Ebert LM, Nicholaou T, Browning J, Russell SE, Zuber M, Jackson HM, Dimopoulos N, Tan BS, Hoos A, Luescher IF, Davis ID, Chen W, Cebon J. Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4. Clin Cancer Res 2009, 15(7):2507-13. 10.1158/1078-0432.CCR-08-2424, 19318477.
16. Gilboa E. The risk of autoimmunity associated with tumor immunotherapy. Nat Immunol 2001, 2(9):789-92. 10.1038/ni0901-789, 11526387.
17. Kessler JH, Melief CJ. Identification of T-cell epitopes for cancer immunotherapy. Leukemia 2007, 21(9):1859-74. 10.1038/sj.leu.2404787, 17611570.
18. Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapy. Semin Immunol 2008, 20(5):276-85. 10.1016/j.smim.2008.07.001, 18684640.
19. Kuan CT, Wakiya K, Herndon JE, Lipp ES, Pegram CN, Riggins GJ, Rasheed A, Szafranski SE, McLendon RE, Wikstrand CJ, Bigner DD. MRP3: a molecular target for human glioblastoma multiforme immunotherapy. BMC Cancer 2010, 10:468. 10.1186/1471-2407-10-468, 2940806, 20809959.
20. Kuan CT, Srivastava N, McLendon RE, Marasco WA, Zalutsky MR, Bigner DD. Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. Int J Cancer 2010, 127(3):598-611. 10.1002/ijc.25062, 19937796.
21. Linnebacher M, Gebert J, Rudy W, Woerner S, Yuan YP, Bork P, von Knebel Doeberitz M. Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens. Int J Cancer 2001, 93(1):6-11. 10.1002/ijc.1298, 11391614.
22. Hans-Georg R, Jutta B, Niels Nikolaus E, Oskar Alexander B, Stefan S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999, 50:213-219. 10.1007/s002510050595, 10602881.
23. Linnebacher M, Wienck A, Boeck I, Klar E. Identification of an MSI-H tumor-specific cytotoxic T cell epitope generated by the (-1) frame of U79260(FTO). J Biomed Biotechnol 2010, 2010:841451. 2842904, 20339516.
24. Arjomand-Nahad F, Diefenbach K, Landt O, Gaikovitch E, Roots I. Genotyping of the triallelic variant G2677T/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes. Anal Biochem 2004, 34:201-3.
25. Pals G, Pindolia K, Worsham MJ. A rapid and sensitive approach to mutation detection using real-time polymerase chain reaction and melting curve analyses, using BRCA1 as an example. Mol Diagn 1999, 4:241-6. 10.1016/S1084-8592(99)80027-7, 10553024.
26. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity 1999, 10:673-9. 10.1016/S1074-7613(00)80066-7, 10403642.
27. Huls M, Russel FG, Masereeuw RJ. The role of ATP binding cassette transporters in tissue defense and organ regeneration. Pharmacol Exp Ther 2009, 328(1):3-9.
28. Callaghan R, Crowley E, Potter S, Kerr ID. P-glycoprotein: so many ways to turn it on. J Clin Pharmacol 2008, 48(3):365-78. 10.1177/0091270007311568, 18156365.
29. Nakai E, Park K, Yawata T, Chihara T, Kumazawa A, Nakabayashi H, Shimizu K. Enhanced MDR1 expression and chemoresistance of cancer stem cells derived from glioblastoma. Cancer Invest 2009, 27(9):901-8. 10.3109/07357900801946679, 19832037.
30. Mannarini L, Bertino G, Morbini P, Villa C, Benazzo M. Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation. Acta Otorhinolaryngol Ital 2007, 27(4):173-80. 2640025, 17957847.
31. Tan BT, Park CY, Ailles LE, Weissman IL. The cancer stem cell hypothesis: a work in progress. Lab Invest 2006, 86(12):1203-7. 10.1038/labinvest.3700488, 17075578.
32. Correa I, Plunkett T. Update on HER-2 as a target for cancer therapy: HER2/neu peptides as tumour vaccines for T cell recognition. Breast Cancer Res 2001, 3(6):399-403. 10.1186/bcr330, 138708, 11737893.
33. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005, 105(7):2640-53. 10.1182/blood-2004-08-3097, 15618470.
34. Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC. Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin. Cancer Immunol Immunother 2006, 55(10):1294-8. 10.1007/s00262-005-0102-x, 16315030.
35. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene 2002, 21(4):674-9. 10.1038/sj.onc.1205074, 11850795.
36. Yamada A, Kawano K, Koga M, Matsumoto T, Itoh K. Multidrug resistance-associated protein 3 is a tumor rejection antigen recognized by HLA-A2402-restricted cytotoxic T lymphocytes. Cancer Res 2001, 61(17):6459-66.